普瑞巴林联合度洛西汀治疗老年痛性糖尿病周围神经病变患者的效果

Effects of Pregabalin combined with Duloxetine in treatment of elderly patients with painful diabetic peripheral neuropathy

目的:观察普瑞巴林联合度洛西汀治疗老年痛性糖尿病周围神经病变患者的效果。方法:选取102例老年痛性糖尿病周围神经病变患者为研究对象,按照随机数字表法分为观察组与对照组各51例。两组均常规控制血糖,在此基础上,对照组给予盐酸度洛西汀肠溶片治疗,观察组在对照组基础上给予普瑞巴林胶囊治疗,比较两组疗效、治疗前后疼痛数字评分法(NRS)评分、疼痛视觉模拟评分法(VAS)评分和不良反应发生率。结果:观察组治疗总有效率为98.04%,明显高于对照组的84.31%,差异有统计学意义(P<0.05);治疗7、14 d后,两组NRS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗7、14 d后,两组VAS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论:普瑞巴林联合度洛西汀治疗老年痛性糖尿病周围神经病变患者可提高治疗总有效率,降低NRS、VAS评分,效果优于单纯度洛西汀治疗。

Objective: To observer effects of Pregabalin combined with Duloxetine in treatment of elderly patients with painful diabetic peripheral neuropathy. Methods: 102 elderly patients with painful diabetic peripheral neuropathy were selected as the research objects and were divided into observation group and control group according to the random number table method, 51 cases in each. Blood glucose was routinely controlled in both groups. On this basis, the control group was given Duloxetine hydrochloride enteric-coated tablets, while the observation group was given Pregabalin capsules on the basis of that of the control group. The curative effects, the pain numerical rating scale(NRS) score, the pain visual analog scale(VAS) score and the incidence of adverse reactions were compared between the two groups before and after the treatment. Results: The total effective rate of the observation group was 98.04%, which was significantly higher than the control group of 84.31%, and the difference was statistically significant(P<0.05). After 7 and 14 days of treatment, the NRS scores of the two groups were lower than those before the treatment;that of the observation group was lower than that of the control group;and the difference was statistically significant(P<0.05). After 7 and 14 days of treatment, the VAS scores of both groups were lower than those before the treatment;that of the observation group was lower than that of the control group;and the difference was statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups during the treatment(P>0.05). Conclusions: Pregabalin combined with Duloxetine in the treatment of the elderly patients with painful diabetic peripheral neuropathy can improve the total effective rate of treatment, and reduce the NRS and VAS score. Moreover, it is superior to single Duloxetine treatment.